Christoffer W. Tornøe

3.9k total citations · 1 hit paper
29 papers, 2.5k citations indexed

About

Christoffer W. Tornøe is a scholar working on Statistics and Probability, Molecular Biology and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Christoffer W. Tornøe has authored 29 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Statistics and Probability, 8 papers in Molecular Biology and 8 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Christoffer W. Tornøe's work include Statistical Methods in Clinical Trials (9 papers), Pharmaceutical studies and practices (7 papers) and Pharmacogenetics and Drug Metabolism (4 papers). Christoffer W. Tornøe is often cited by papers focused on Statistical Methods in Clinical Trials (9 papers), Pharmaceutical studies and practices (7 papers) and Pharmacogenetics and Drug Metabolism (4 papers). Christoffer W. Tornøe collaborates with scholars based in United States, Denmark and Sweden. Christoffer W. Tornøe's co-authors include Helen M. Colhoun, Ildiko Lingvay, Tuğçe Kalaycı Oral, Marie Mide Michelsen, Jorge Plutzky, A. Michael Lincoff, G. Kees Hovingh, John Deanfield, Robert F. Kushner and Donna H. Ryan and has published in prestigious journals such as New England Journal of Medicine, The Journal of Clinical Endocrinology & Metabolism and Clinical Cancer Research.

In The Last Decade

Christoffer W. Tornøe

29 papers receiving 2.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes

2023 1.3k citations A. Michael Lincoff, Kirstine Brown‐Frandsen et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Christoffer W. Tornøe United States	18	1.0k	623	565	554	352	29	2.5k
Andrea Jorgensen United Kingdom	32	405 0.4×	468 0.8×	629 1.1×	509 0.9×	287 0.8×	107	3.7k
Larisa H. Cavallari United States	40	861 0.8×	685 1.1×	593 1.0×	1.3k 2.3×	529 1.5×	198	5.3k
Ingrid Glurich United States	29	485 0.5×	597 1.0×	176 0.3×	327 0.6×	370 1.1×	88	3.0k
Niclas Eriksson Sweden	23	856 0.8×	486 0.8×	416 0.7×	1.2k 2.2×	260 0.7×	67	4.2k
Deepak Voora United States	27	609 0.6×	719 1.2×	338 0.6×	802 1.4×	774 2.2×	102	3.6k
Hui Yin Canada	31	1.1k 1.1×	748 1.2×	240 0.4×	362 0.7×	523 1.5×	92	2.8k
Peter Fenici Italy	23	2.2k 2.1×	910 1.5×	247 0.4×	501 0.9×	688 2.0×	98	2.9k
Ulrich Broeckel United States	37	295 0.3×	1.1k 1.8×	179 0.3×	633 1.1×	506 1.4×	95	3.9k
Suzette J. Bielinski United States	33	308 0.3×	844 1.4×	140 0.2×	844 1.5×	358 1.0×	154	3.7k
Charles S. Eby United States	22	418 0.4×	271 0.4×	164 0.3×	754 1.4×	385 1.1×	61	3.0k

Countries citing papers authored by Christoffer W. Tornøe

Since Specialization

Citations

This map shows the geographic impact of Christoffer W. Tornøe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christoffer W. Tornøe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christoffer W. Tornøe more than expected).

Fields of papers citing papers by Christoffer W. Tornøe

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christoffer W. Tornøe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christoffer W. Tornøe. The network helps show where Christoffer W. Tornøe may publish in the future.

Co-authorship network of co-authors of Christoffer W. Tornøe

This figure shows the co-authorship network connecting the top 25 collaborators of Christoffer W. Tornøe. A scholar is included among the top collaborators of Christoffer W. Tornøe based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christoffer W. Tornøe. Christoffer W. Tornøe is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Baker, Jennifer L., Carine de Beaufort, Ruth M. Belin, et al.. (2024). Considerations for the design and conduct of pediatric obesity pharmacotherapy clinical trials: Proceedings of expert roundtable meetings. Pediatric Obesity. 19(11). e13161–e13161. 2 indexed citations

Brown‐Frandsen, Kirstine, Helen M. Colhoun, John Deanfield, et al.. (2024). Semaglutide and cardiovascular outcomes in patients with overweight or obesity who do not have diabetes. Obesity Research & Clinical Practice. 18(5). S36–S36. 1 indexed citations

Lincoff, A. Michael, Kirstine Brown‐Frandsen, Helen M. Colhoun, et al.. (2023). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine. 389(24). 2221–2232. 1260 indexed citations breakdown →

Garnett, Christine, Peter L. Bonate, Qianyu Dang, et al.. (2017). Scientific white paper on concentration-QTc modeling. Journal of Pharmacokinetics and Pharmacodynamics. 45(3). 383–397. 170 indexed citations

Dykstra, Kevin, Nitin Mehrotra, Christoffer W. Tornøe, et al.. (2015). Reporting guidelines for population pharmacokinetic analyses. Journal of Pharmacokinetics and Pharmacodynamics. 42(3). 301–314. 26 indexed citations

Carção, Manuel, Bryce A. Kerlin, Andrew Will, et al.. (2015). Pharmacokinetic characterization of recombinant factor XIII (FXIII)‐A2 across age groups in patients with FXIII A‐subunit congenital deficiency. Haemophilia. 21(3). 380–385. 9 indexed citations

Garnett, Christine, Jogarao Gobburu, Venkatesh Atul Bhattaram, et al.. (2011). Impact of Pharmacometric Analyses on New Drug Approval and Labelling Decisions. Clinical Pharmacokinetics. 50(10). 627–635. 112 indexed citations

Florian, Jeffry, Christoffer W. Tornøe, Richard C. Brundage, Ameeta Parekh, & Christine Garnett. (2011). Population Pharmacokinetic and Concentration-QTc Models for Moxifloxacin: Pooled Analysis of 20 Thorough QT Studies. The Journal of Clinical Pharmacology. 51(8). 1152–1162. 136 indexed citations

Ingwersen, Steen H., Rajanikanth Madabushi, Estelle Watson, et al.. (2011). Dosing Rationale for Liraglutide in Type 2 Diabetes Mellitus: A Pharmacometric Assessment. The Journal of Clinical Pharmacology. 52(12). 1815–1823. 32 indexed citations

10.

Krudys, Kevin, Jeffry Florian, Christoffer W. Tornøe, et al.. (2011). Knowledge management for efficient quantitative analyses during regulatory reviews. Expert Review of Clinical Pharmacology. 4(6). 697–703. 6 indexed citations

11.

Romero, Klaus, Brian Corrigan, Christoffer W. Tornøe, et al.. (2010). Pharmacometrics as a Discipline Is Entering the “Industrialization” Phase: Standards, Automation, Knowledge Sharing, and Training Are Critical for Future Success. The Journal of Clinical Pharmacology. 50(S9). 9S–19S. 17 indexed citations

12.

Brave, Michael H., Ann T. Farrell, Sarah Pope Miksinski, et al.. (2010). FDA Review Summary: Mozobil in Combination with Granulocyte Colony-Stimulating Factor to Mobilize Hematopoietic Stem Cells to the Peripheral Blood for Collection and Subsequent Autologous Transplantation. Oncology. 78(3-4). 282–288. 100 indexed citations

13.

Malik, Shakun, Ke Liu, Qiang Xu, et al.. (2010). Folotyn (Pralatrexate Injection) for the Treatment of Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma: U.S. Food and Drug Administration Drug Approval Summary. Clinical Cancer Research. 16(20). 4921–4927. 38 indexed citations

14.

Bhattaram, Venkatesh Atul, Charles R. Bonapace, John Duan, et al.. (2007). Impact of Pharmacometric Reviews on New Drug Approval and Labeling Decisions—a Survey of 31 New Drug Applications Submitted Between 2005 and 2006. Clinical Pharmacology & Therapeutics. 81(2). 213–221. 85 indexed citations

15.

Jadhav, Pravin, Henrik Agersø, Christoffer W. Tornøe, & Jogarao Gobburu. (2006). Semi-Mechanistic Pharmacodynamic Modeling for Degarelix, a Novel Gonadotropin Releasing Hormone (GnRH) Blocker. Journal of Pharmacokinetics and Pharmacodynamics. 33(5). 609–634. 16 indexed citations

16.

Bjarnason, N. H., et al.. (2006). Optimizing Lithium Dosing in Hemodialysis. Therapeutic Drug Monitoring. 28(2). 262–266. 9 indexed citations

17.

Tornøe, Christoffer W.. (2005). Population pharmacokinetic/pharmacodynamic modelling of the hypothalamic-pituitary-gonadal axis. 1 indexed citations

18.

Tornøe, Christoffer W., Rune Viig Overgaard, Henrik Agersø, et al.. (2005). Stochastic Differential Equations in NONMEM®: Implementation, Application, and Comparison with Ordinary Differential Equations. Pharmaceutical Research. 22(8). 1247–1258. 50 indexed citations

19.

Tornøe, Christoffer W., Henrik Agersø, E. Niclas Jonsson, Henrik Madsen, & Henrik Aalborg Nielsen. (2004). Non-linear mixed-effects pharmacokinetic/pharmacodynamic modelling in NLME using differential equations. Computer Methods and Programs in Biomedicine. 76(1). 31–40. 36 indexed citations

20.

Tornøe, Christoffer W., Henrik Agersø, Henrik Aalborg Nielsen, Henrik Madsen, & E. Niclas Jonsson. (2004). Population Pharmacokinetic Modeling of a Subcutaneous Depot for GnRH Antagonist Degarelix. Pharmaceutical Research. 21(4). 574–584. 27 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact